GreenPeptide achieves milestone of 1.2 billion yen in fundraising

Completion of fundraising in the amount of approximately 1.2 billion yen through GreenPeptide and venture capitalists
GreenPeptide has actively started the global development program of GRN-1201, following ITK-1.

On August 29, 2014, GreenPeptide Co., Ltd (head office: Kurume-shi Fukuoka Prefecture, CEO Kenichi Nagai, hereafter referred to as "GreenPeptide) has completed raising funds totaling 1.2 billion yen, consisting of funds managed by the venture capitalists shown below:

Innovation Engine Inc. (Minato-ku Tokyo, CEO Mustunori Sano)
ibis Capital Partners, Inc. (Chuo-ku Tokyo, CEO Kiichiro Chujo)
MBL Venture Capital Co., Ltd. (Nagoya-shi Aichi Prefecture, CEO Yasuyo Kayama)
Nippon Venture Capital Co., Ltd. (Minato-ku Tokyo, CEO Shuichi Okuhara)

This round of fundraising was completed with Innovation Engine Inc. as the lead investor.

Following the acquisition of funds, the development of a global cancer vaccine in the US will be initiated following that of the ITK-1 prostate cancer vaccine, which is undergoing a phase III domestic clinical trial in Japan run by together with the licensee, FUJIFILM Corporation.

In recent years, the "cancer vaccine" has emerged as the fourth modality of cancer therapy for patients who are resistant to conventional therapies such as surgery, radiotherapy, and chemotherapy, and has been paid more attention. The administration of cancer cell-specific peptide antigens enhances the human body's own immune systems and helps it to fight against cancer. Compared to chemotherapy and radiotherapy, there are less side effects. It can be expected to have life-prolonging effects. The research and development of cancer vaccines is actively ongoing over the world.

GreenPeptide has been developing cancer vaccines that stimulate and enhance the pre-existing immunity of the patient to fight cancer cells. By taking advantage of this different approach from previously developed cancer vaccines, it is intended to have more rapid and efficient boosting effect to fight cancer before deterioration.

■GreenPeptide Company Overview
Name: GreenPeptide Co., Ltd. ［http://www.green-peptide.com/］
Business Content: Development of new cancer vaccines
Representative: CEO Kenichi Nagai
Location: 1-1 Hyakunenkoen Kurume-shi Fukuoka
Establishment Date: May 8, 2003
GreenPeptide Co., Ltd. was established as a company that produces and commercializes novel pharmaceutical innovations that have been subjected to basic/clinical research at the Department of Immunology and Immunotherapy, Kurume University, School of Medicine

For inquiries regarding this company and the products and services provided, please contact the following: Tokyo Branch Management Department, Tel.: 03-5840-7697